Log in

NYSEAMERICAN:NNVCNanoViricides Stock Price, Forecast & News

$7.25
+0.08 (+1.12 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.01
Now: $7.25
$7.39
50-Day Range N/A
52-Week Range
$1.27
Now: $7.25
$19.20
Volume198,432 shs
Average Volume2.64 million shs
Market Capitalization$65.78 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as injectable and oral anti-influenza nanoviricide drug for H7N9, Bird Flu H5N1, other Highly Pathogenic Influenzas, Epidemic Influenzas, and Seasonal Influenzas; DengueCide, an anti-dengue nanoviricide which is in pre-clinical development; and HIVCide, an anti-human immunodeficiency virus drug candidate. It is also developing HerpeCide, a skin cream for the treatment of cold sores and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:NNVC
Previous SymbolNYSEMKT:NNVC
CUSIPN/A
Phone+1-203-9376137

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees7
Market Cap$65.78 million
Next Earnings Date8/28/2020 (Estimated)
OptionableOptionable

Receive NNVC News and Ratings via Email

Sign-up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter.

NanoViricides (NYSEAMERICAN:NNVC) Frequently Asked Questions

When is NanoViricides' next earnings date?

NanoViricides is scheduled to release its next quarterly earnings announcement on Friday, August 28th 2020. View our earnings forecast for NanoViricides.

How were NanoViricides' earnings last quarter?

NanoViricides Inc (NYSEAMERICAN:NNVC) issued its quarterly earnings data on Tuesday, February, 19th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by $0.08. View NanoViricides' earnings history.

When did NanoViricides' stock split? How did NanoViricides' stock split work?

Shares of NanoViricides reverse split before market open on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of NanoViricides stock prior to the reverse split would have 5 shares after the split.

Has NanoViricides been receiving favorable news coverage?

Headlines about NNVC stock have trended negative on Sunday, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NanoViricides earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days. View the latest news about NanoViricides.

Are investors shorting NanoViricides?

NanoViricides saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 303,800 shares, a drop of 30.8% from the May 31st total of 438,900 shares. Based on an average daily volume of 997,600 shares, the short-interest ratio is currently 0.3 days. Currently, 3.9% of the shares of the company are sold short. View NanoViricides' Current Options Chain.

Who are some of NanoViricides' key competitors?

What other stocks do shareholders of NanoViricides own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), Micron Technology (MU), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Domino's Pizza (DPZ), AbbVie (ABBV), Novavax (NVAX), Vaxart (VXRT) and NVIDIA (NVDA).

Who are NanoViricides' key executives?

NanoViricides' management team includes the following people:
  • Dr. Anil R. Diwan, Chairman, Pres & Sec. (Age 60)
  • Ms. Meeta R. Vyas SB, MBA, Chief Financial Officer (Age 60)
  • Dr. Eugene Seymour, Chief Exec. Officer Emeritus (Age 78)
  • Dr. Randall W. Barton Ph.D., Chief Scientific Officer & Chief Regulatory Officer (Age 72)
  • Dr. Irach B. Taraporewala, Consultant & Director (Age 63)

What is NanoViricides' stock symbol?

NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC."

How do I buy shares of NanoViricides?

Shares of NNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NanoViricides' stock price today?

One share of NNVC stock can currently be purchased for approximately $7.25.

How big of a company is NanoViricides?

NanoViricides has a market capitalization of $65.78 million. NanoViricides employs 7 workers across the globe.

What is NanoViricides' official website?

The official website for NanoViricides is www.nanoviricides.com.

How can I contact NanoViricides?

NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The company can be reached via phone at +1-203-9376137.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.